The present invention relates to a method of producing a compound of formula (I) or a salt of a compound of formula (I). The invention also relates to a compound of formula (I) or a salt of a compound of formula (I) for use in a therapeutic method to achieve one or more therapeutic effects as well as for use in the treatment and/or prevention of certain diseases. Furthermore, the invention provides a pharmaceutical composition comprising one or more compound(s) of formula (I) or salt(s) of compound(s) of formula (I).

A method for producing diglycerides is provided. The method includes combining (i) an oil comprising at least one polyunsaturated fatty acid in the form of ethyl esters, free fatty acids, and/or combinations thereof, (ii) lipase, and (iii) glycerol in water to produce diglycerides with a high level of purity. Highly pure diglycerides obtained according to the method are also provided.

A method for producing diglycerides is provided. The method includes combining (i) an oil comprising at least one polyunsaturated fatty acid in the form of ethyl esters, free fatty acids, and/or combinations thereof, (ii) lipase, and (iii) glycerol in water to produce diglycerides with a high level of purity. Highly pure diglycerides obtained according to the method are also provided.

The invention relates to triesters of cyclohexanetripropionic acid, preparation thereof and use thereof as plasticizers for polymers wherein examples of the triester of cyclohexanetripropionic acid include tri(.sup.nbutyl) cyclohexane-1,2,4-tripropionate, tri(methylpropyl) cyclohexane-1,2,4-tripropionate, tri(.sup.npentyl) cyclohexane-1,2,4-tripropionate, tri(.sup.isopentyl) cyclohexane-1,2,4-tripropionate, tri(2-methylbutyl) cyclohexane-1,2,4-tripropionate, tri(3-methylbutyl) cyclohexane-1,2,4-tripropionate, tri(.sup.nhexyl) cyclohexane-1,2,4-tripropionate, tri(.sup.isohexyl) cyclohexane-1,2,4-tripropionate, tri(.sup.nheptyl) cyclohexane-1,2,4-tripropionate, tri(.sup.isoheptyl) cyclohexane-1,2,4-tripropionate, tri(.sup.noctyl) cyclohexane-1,2,4-tripropionate, tri(.sup.isooctyl) cyclohexane-1,2,4-tripropionate, tri(2-ethylhexyl) cyclohexane-1,2,4-tripropionate, tri(.sup.nnonyl) cyclohexane-1,2,4-tripropionate, tri(.sup.isononyl) cyclohexane-1,2,4-tripropionate, tri(.sup.ndecyl) cyclohexane-1,2,4-tripropionate, tri(.sup.isodecyl) cyclohexane-1,2,4-tripropionate, and tri(2-propylheptyl) cyclohexane-1,2,4-tripropionate.

The invention relates to triesters of cyclohexanetripropionic acid, preparation thereof and use thereof as plasticizers for polymers wherein examples of the triester of cyclohexanetripropionic acid include tri(.sup.nbutyl) cyclohexane-1,2,4-tripropionate, tri(methylpropyl) cyclohexane-1,2,4-tripropionate, tri(.sup.npentyl) cyclohexane-1,2,4-tripropionate, tri(.sup.isopentyl) cyclohexane-1,2,4-tripropionate, tri(2-methylbutyl) cyclohexane-1,2,4-tripropionate, tri(3-methylbutyl) cyclohexane-1,2,4-tripropionate, tri(.sup.nhexyl) cyclohexane-1,2,4-tripropionate, tri(.sup.isohexyl) cyclohexane-1,2,4-tripropionate, tri(.sup.nheptyl) cyclohexane-1,2,4-tripropionate, tri(.sup.isoheptyl) cyclohexane-1,2,4-tripropionate, tri(.sup.noctyl) cyclohexane-1,2,4-tripropionate, tri(.sup.isooctyl) cyclohexane-1,2,4-tripropionate, tri(2-ethylhexyl) cyclohexane-1,2,4-tripropionate, tri(.sup.nnonyl) cyclohexane-1,2,4-tripropionate, tri(.sup.isononyl) cyclohexane-1,2,4-tripropionate, tri(.sup.ndecyl) cyclohexane-1,2,4-tripropionate, tri(.sup.isodecyl) cyclohexane-1,2,4-tripropionate, and tri(2-propylheptyl) cyclohexane-1,2,4-tripropionate.

The invention relates to a method for producing optionally functionalized acyl-capped (acyl-blocked) 3-hydroxybutyric acids and their salts and esters as well as to the products thus obtained and their use.

The invention relates to a method for producing optionally functionalized acyl-capped (acyl-blocked) 3-hydroxybutyric acids and their salts and esters as well as to the products thus obtained and their use.

A process for the production of an ester product from a mixture of at least two different ester compounds includes the steps of mixing together at least two different starting ester compounds to form a first ester mixture; and contacting the first ester mixture with a catalyst including from 30-60% of calcium oxide and at least one second metal oxide at a temperature of at least 180° C., for a duration of at least one hour, with mixing, to form a second ester mixture having a melting point which is lower than the melting point of the first ester mixture.

A process for the production of an ester product from a mixture of at least two different ester compounds includes the steps of mixing together at least two different starting ester compounds to form a first ester mixture; and contacting the first ester mixture with a catalyst including from 30-60% of calcium oxide and at least one second metal oxide at a temperature of at least 180° C., for a duration of at least one hour, with mixing, to form a second ester mixture having a melting point which is lower than the melting point of the first ester mixture.

The present invention provides crystalline solid and amorphous forms of (−)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (−)-halofenate.